Topic:

Clinical Trials

Latest Headlines

Latest Headlines

Amgen completes PhIII trifecta as AMG416 goes head-to-head with Sensipar

Amgen hit the trifecta with a successful conclusion to its third, and last, Phase III study of AMG416, a new drug for secondary hyperparathyroidism which handily beat out its in-house rival Sensipar in a head-to-head study.

Department of Defense gives contractor $14.8M to test so-called Sample-to-Sequence system

The Department of Defense has a habit of funding new medical technologies. This week it awarded a government contractor MRIGlobal $14.8 million for its proposed Sample-to-Sequence system to sequence the entire genome of pathogens and give a diagnosis within 24 hours.

Exclusive: Regeneron, Sanofi outline promising PhIIb data for top blockbuster pick dupilumab

Regeneron and its close partner Sanofi have posted another set of promising results for dupilumab--which targets the interleukin-4 and interleukin-13 inflammatory proteins--from a Phase IIb study that backs up those high expectations.

HIV vaccine trial kicks off in South Africa

Researchers have launched a clinical trial in South Africa--dubbed HVTN 100--to evaluate a candidate HIV vaccine regimen for safety and the immune response it triggers.

Novavax's Ebola vaccine is in hot pursuit of GSK, Merck, J&J candidates

Novavax announced on Thursday that it would take its Ebola candidate to Australia for a Phase I trial involving 230 healthy adults. It is the fourth company to bring an Ebola vaccine to human trials, but Novavax says it has a better vaccine.

Takeda's lung cancer drug motesanib fails--again--in Phase III odyssey

Three years after Takeda decided to double down on motesanib for non-small cell lung cancer, in-licensing full rights to the drug from Amgen following their big Phase III failure in 2011, the company has once again come up empty-handed in a major late-stage test of the therapy.

VBL craters after PhII psoriasis and ulcerative colitis flops, decision to punt drug

It took a while for VBL Therapeutics to actually complete its IPO last year. And this morning it may be wishing it hadn't succeeded as its stock price crashed following the failure of its midstage studies of a new drug for psoriasis and ulcerative colitis.

Advaxis inks pact with Incyte to test cervical cancer vaccine combo

Advaxis, on a partnering spree after joining with Merck and AstraZeneca to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte to trial one of its prospects in cervical cancer.

MerLion becomes first homegrown Singapore company to win U.S. FDA novel drug nod

SINGAPORE-- MerLion Pharmaceuticals announced Wednesday that the U.S. FDA has approved an otic suspension of finafloxacin to treat acute otitis externa, commonly known as "swimmer's ear."

Cellular Biomedicine inks CAR-T deal with Chinese General Hospital

SINGAPORE-- Cellular Biomedicine Group has bought chimeric antigen receptor T cell therapies from the Chinese PLA General Hospital in a deal valued at RMB12 million ($1.9 million) to be paid in three installments.